4CPS-021 Effectiveness, persistence, and adherence of baricitinib in rheumatoid arthritis: long-term real-world evidence study

Background and ImportanceBaricitinib (BAR) is a Janus kinase inhibitor (JAKi) selective for isoenzymes 1 and 2. It is used in rheumatoid arthritis (RA) with an inadequate response to conventional synthetic disease-modifying drugs (csDMARD).Aim and ObjectivesThe objective was to evaluate the effectiv...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A31-A31
Main Authors: Calvo García, A, Ramirez Herraiz, E, Llorente Cubas, I, Varas de Dios, B, Morell Baladrón, A, Benedí González, J, García de Vicuña, R
Format: Article
Language:English
Subjects:
Conflicts of interest
Kinases
Remission (Medicine)
Rheumatoid arthritis
Section 4: Clinical pharmacy services
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and ImportanceBaricitinib (BAR) is a Janus kinase inhibitor (JAKi) selective for isoenzymes 1 and 2. It is used in rheumatoid arthritis (RA) with an inadequate response to conventional synthetic disease-modifying drugs (csDMARD).Aim and ObjectivesThe objective was to evaluate the effectiveness, persistence, and adherence of BAR in RA in a real-world setting.Material and MethodsAn ambispective observational study was designed in a third-level hospital. Patients with RA who started BAR between September 2017 and June 2021 were included and signed an informed consent. Patients participating in a clinical trial were excluded. Patients were followed up until December 2021. Effectiveness was evaluated by variation of the Disease Activity Score (28-joint count) using C-reactive protein (DAS28PCR); and by the percentage of patients achieving therapeutic target: low disease activity (LDA) (DAS28CRP≤3.2) or disease remission (DAS28CRP0,8). According to the CQR5, all patients were ‘good adherers’.Conclusion and RelevanceJAKi are the most recent alternative available for RA treatment. BAR demonstrated effectiveness in our study cohort, with a significant decrease in DAS28PCR, a high percentage of patients reaching the therapeutic target, and a persistence exceeding two years. Adherence to treatment was very high, almost 100%. More studies in real-world setting are needed to confirm these results.References and/or
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2023-eahp.66